Related Experiment Videos
[Autoimmune thrombocytopenia and pregnancy]
R Anselmi Angeli1, S Ronca, F Bechini
1Divisione di Ostetricia e Ginecologia, Azienda Complesso Ospedaliero S. Filippo Neri, Roma.
Minerva Ginecologica
|December 1, 1996
Summary
Immune thrombocytopenic purpura (ITP) in pregnant women can pose risks to both mother and fetus. Corticosteroid treatment is often effective, though not always successful, in managing this autoimmune condition.
Area of Science:
- Obstetrics and Gynecology
- Immunology
- Hematology
Background:
- Immune thrombocytopenic purpura (ITP) is an autoimmune disorder affecting young women of reproductive age.
- Diagnosis of maternal thrombocytopenia during pregnancy is increasing due to routine complete blood count monitoring.
- Platelet autoantibodies can lead to increased platelet destruction and pose risks to the fetus.
Observation:
- Maternal IgG autoantibodies can cross the placenta, potentially causing fetal thrombocytopenia and bleeding complications like intracranial hemorrhage.
- Four pregnant patients with thrombocytopenia were treated with corticosteroids (prednisone 1 mg/kg/day).
Findings:
- Corticosteroid therapy demonstrated successful outcomes in most cases.
- One patient did not respond to corticosteroid treatment.
- No intracranial hemorrhages were observed in the treated patients, suggesting a lower risk than previously assumed.
Implications:
- Corticosteroids are a primary treatment choice for pregnant women with ITP.
- While generally effective, corticosteroid therapy may not yield a clinical response in all cases.
- The study suggests that the risk of fetal or neonatal hemorrhage in ITP pregnancies may be lower than commonly believed.